Cover Image
市場調查報告書

Pharming Group N.V.的產品平台分析

Pharming Group N.V. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 200990
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Pharming Group N.V.的產品平台分析 Pharming Group N.V. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 35 Pages
簡介

Pharming Group N.V.是在荷蘭設立總公司的生物製藥企業,進行著遺傳性疾病,老齡化障礙,外科手術的出血,外傷性出血等對應未滿足需求的治療性蛋白質及營養劑的開發、製造、商品化。

本報告提供Pharming Group N.V.的治療藥開發平台的現狀及各開發階段比較分析、藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Pharming Group N.V.的基本資料

  • Pharming Group N.V.概要
  • 主要資訊
  • 企業資料

Pharming Group N.V.:R&D概要

  • 主要的治療範圍

Pharming Group N.V.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Pharming Group N.V.:開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Pharming Group N.V.:藥物簡介

  • C1 esterase inhibitor (recombinant)
  • Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease
  • Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease
  • Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease
  • Recombinant Enzyme to Replace Factor IX for Hemophilia B
  • Recombinant Human Collagen Type 1
  • rhFactor VIII

Pharming Group N.V.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Pharming Group N.V.:最新的開發平台資訊

Pharming Group N.V.:開發暫停中的計劃

Pharming Group N.V.:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Pharming Group N.V.:企業理念

Pharming Group N.V.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07100CDB

Summary

Global Markets Direct's, 'Pharming Group N.V. - Product Pipeline Review - 2015', provides an overview of the Pharming Group N.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharming Group N.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharming Group N.V. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharming Group N.V.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharming Group N.V.'s pipeline products

Reasons to buy

  • Evaluate Pharming Group N.V.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharming Group N.V. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharming Group N.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharming Group N.V. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharming Group N.V.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharming Group N.V. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharming Group N.V. Snapshot
    • Pharming Group N.V. Overview
    • Key Information
    • Key Facts
  • Pharming Group N.V. - Research and Development Overview
    • Key Therapeutic Areas
  • Pharming Group N.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Pharming Group N.V. - Pipeline Products Glance
    • Pharming Group N.V. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Pharming Group N.V. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Pharming Group N.V. - Drug Profiles
    • C1 esterase inhibitor (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Alpha Glucosidase for Pompe Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Factor IX for Hemophilia B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Replace Factor VIII for Hemophilia A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharming Group N.V. - Pipeline Analysis
    • Pharming Group N.V. - Pipeline Products by Target
    • Pharming Group N.V. - Pipeline Products by Route of Administration
    • Pharming Group N.V. - Pipeline Products by Molecule Type
    • Pharming Group N.V. - Pipeline Products by Mechanism of Action
  • Pharming Group N.V. - Recent Pipeline Updates
  • Pharming Group N.V. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • fibrinogen
  • Pharming Group N.V. - Company Statement
  • Pharming Group N.V. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharming Group N.V., Key Information
  • Pharming Group N.V., Key Facts
  • Pharming Group N.V. - Pipeline by Indication, 2015
  • Pharming Group N.V. - Pipeline by Stage of Development, 2015
  • Pharming Group N.V. - Monotherapy Products in Pipeline, 2015
  • Pharming Group N.V. - Phase II, 2015
  • Pharming Group N.V. - Preclinical, 2015
  • Pharming Group N.V. - Discovery, 2015
  • Pharming Group N.V. - Pipeline by Target, 2015
  • Pharming Group N.V. - Pipeline by Route of Administration, 2015
  • Pharming Group N.V. - Pipeline by Molecule Type, 2015
  • Pharming Group N.V. - Pipeline Products by Mechanism of Action, 2015
  • Pharming Group N.V. - Recent Pipeline Updates, 2015
  • Pharming Group N.V. - Discontinued Pipeline Products, 2015
  • Pharming Group N.V., Subsidiaries

List of Figures

  • Pharming Group N.V. - Pipeline by Top 10 Indication, 2015
  • Pharming Group N.V. - Pipeline by Stage of Development, 2015
  • Pharming Group N.V. - Monotherapy Products in Pipeline, 2015
  • Pharming Group N.V. - Pipeline by Top 10 Target, 2015
  • Pharming Group N.V. - Pipeline by Top 10 Route of Administration, 2015
  • Pharming Group N.V. - Pipeline by Top 10 Molecule Type, 2015
  • Pharming Group N.V. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top